#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Laryngeal squamous cell carcinoma Fibrodysplasia ossificans progressiva Eosinophilic oesophagitis Progressive supranuclear palsy Liposarcoma recurrent Renal disorder Human papilloma virus immunisation Gastrooesophageal cancer Neuroendocrine carcinoma of the skin Mitochondrial myopathy Oesophageal adenocarcinoma stage II Haemophilia B with anti factor IX Wolfram syndrome Factor VIII deficiency Drug eruption More trials…

    Learn about Rare Diseases

    Hepatic angiosarcoma – Life with Disease Phenylketonuria – Life with Disease Retinitis pigmentosa Marginal zone lymphoma refractory – Treatment Angiosarcoma – Trials in Disease Sarcoidosis – Trials in Disease Andersen-Tawil syndrome – Life with Disease Primary hyperoxaluria Mucopolysaccharidosis – Basic Information Prolymphocytic leukaemia – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tub-040 Naloxone Sulpiride Vancomycin Heparin Sodium SAT-3247 OXALATE Neostigmine Methylsulfate Human Mesenchymal Stem Cells Immunoglobulins, Normal Human Linezolid Pristinamycin Fexofenadine TTX-381 MALIC ACID Rbd1016 Siltuximab Glucocorticoids Pertechnetate (99Mtc) Sodium NVG-2089 Fasudil Hydrochloride More therapies…

    Learn about Your Condition

    Merycism Metastases to biliary tract Lichen sclerosus Ovarian granulosa cell tumour Breast cancer stage I Burning mouth syndrome Mantle cell lymphoma Lung adenocarcinoma stage IV Juvenile psoriatic arthritis Embolism venous Hypereosinophilic syndrome HER2 negative breast cancer Urea cycle disorder Splenic marginal zone lymphoma Pharyngeal cancer stage I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. GRN Klinik Weinheim

GRN Klinik Weinheim

Rtketsfdglnfx Wxeojpyir 6pgwnn Gsykctq

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Germany

  • Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    Germany

  • Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Cyclophosphamide Monohydrate
    • Atezolizumab
    Germany Spain

  • Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Human epidermal growth factor receptor negative
    • Breast cancer
    • Breast cancer female
    Investigated Drugs:
    • Abemaciclib
    Germany Poland Spain

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!